Thirty-one participants received either a placebo or experimental doses of ARO-DIMER-PA in the first human trial of the drug, according to findings released on November 7 by Cleveland Clinic.
The experimental injection targets both low-density lipoprotein cholesterol and triglycerides simultaneously through ribonucleic acid interference.
Unlike traditional therapies that manage blood lipid disorders separately, this dual-pathway approach tackles both types of fat with a single treatment.
Mixed dyslipidemia often requires multiple medications to reach target levels, making combination treatments a growing focus for clinical researchers.
Trial participants experienced reductions in low-density lipoprotein cholesterol ranging from 26% to 65%. Triglyceride levels dropped between 56% and 78% depending on the specific dose administered during the study.
Low-density lipoprotein cholesterol builds up inside artery walls over time, forming plaque that narrows blood vessels and raises cardiovascular risks. Triglycerides store excess energy from the body, and severe elevations in this fat type can trigger acute pancreatitis.
Researchers designed the new drug to silence specific genetic instructions inside liver cells to lower the production of proteins linked to high blood fat. Investigators distributed the 31 participants into groups receiving varying doses or placebos to measure safety and efficacy.
The trial evaluated safety and changes in blood lipid levels rather than long-term cardiovascular events. Current data do not establish whether the injection lowers the actual incidence of heart attacks or strokes in patients over time.
Researchers are planning subsequent clinical trials to evaluate repeated dosing, determine the appropriate dosage, and establish long-term safety profiles. Participants must complete extended follow-up periods before health authorities can assess the full therapeutic value of the treatment.
Low-density lipoprotein cholesterol accumulates in arterial walls to form plaque, while triglycerides store excess body energy. Elevated levels of both fats present distinct health risks, including narrowed arteries and pancreatitis.
The technology targets specific genetic instructions inside liver cells to reduce the production of proteins that raise blood fat levels. This mechanism allows a single experimental treatment to regulate two separate lipid pathways simultaneously.
The drug remains strictly experimental while investigators complete clinical trials to test repeated doses and long-term safety. Researchers must finish upcoming study phases before the treatment can be considered for clinical practice.
Related reading